Patent · US Active

Parenteral formulations

US12064398B2 · kind B2 · utility

7Cited by

47References

13Claims

0Family size

Assignee

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · GB

Inventors

Stephen Wayne Wright · Old Lyme, US
Jitinder WILKHU · Cambridge, GB

Key dates

Filing date	Dec 10, 2021
Grant date	Aug 20, 2024
Priority date	—
Expiry date	Dec 10, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/26
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.